Beckman Coulter Developing Tests to Detect Coronavirus Antibodies
By LabMedica International staff writers Posted on 01 Apr 2020 |
Image: Immunoassay Analyzer Access 2 (Photo courtesy of Beckman Coulter)
Beckman Coulter (Brea, CA, USA) has responded to the global COVID-19 pandemic by developing assays to identify IgM and IgG antibodies to the coronavirus or SARS-CoV-2. The assays will be designed for use on any of the company’s high-throughput Access family of immunoassay systems, including the Access 2 and DxI series installed globally. After finalizing the assays, Beckman Coulter plans to submit them for the FDA's Emergency Use Authorization.
Beckman Coulter’s diagnostic systems are used in complex biomedical testing, and are found in hospitals, reference laboratories and physician office settings around the world. Research has shown that after infection with SARS-CoV-2, viral antigens stimulate the body's immune system to produce antibodies that can be detected with IgM and IgG tests.
"Antibody assays play a critical role in understanding the measure of immunity an individual has developed against SARS-CoV-2," said Kathleen Orland, senior vice president and general manager for Beckman Coulter's chemistry and immunoassay business. "This type of understanding could help determine the identification of those who would require a vaccine once available or when an infected individual could safely return to work."
"With the ability to assess a patient's immunity to SARS-CoV-2, this testing modality may enable clinicians to clear hospital staff, emergency responders, and others to get back to work with an indication that have had prior exposure and therefore may have immunity to the disease," said Shamiram R. Feinglass, M.D., MPH, chief medical officer, Beckman Coulter. "This test also could allow those without immunity to be identified and kept safe until the pandemic subsides."
Related Links:
Beckman Coulter
Beckman Coulter’s diagnostic systems are used in complex biomedical testing, and are found in hospitals, reference laboratories and physician office settings around the world. Research has shown that after infection with SARS-CoV-2, viral antigens stimulate the body's immune system to produce antibodies that can be detected with IgM and IgG tests.
"Antibody assays play a critical role in understanding the measure of immunity an individual has developed against SARS-CoV-2," said Kathleen Orland, senior vice president and general manager for Beckman Coulter's chemistry and immunoassay business. "This type of understanding could help determine the identification of those who would require a vaccine once available or when an infected individual could safely return to work."
"With the ability to assess a patient's immunity to SARS-CoV-2, this testing modality may enable clinicians to clear hospital staff, emergency responders, and others to get back to work with an indication that have had prior exposure and therefore may have immunity to the disease," said Shamiram R. Feinglass, M.D., MPH, chief medical officer, Beckman Coulter. "This test also could allow those without immunity to be identified and kept safe until the pandemic subsides."
Related Links:
Beckman Coulter
Latest COVID-19 News
- New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases
- Long COVID Etiologies Found in Acute Infection Blood Samples
- Novel Device Detects COVID-19 Antibodies in Five Minutes
- CRISPR-Powered COVID-19 Test Detects SARS-CoV-2 in 30 Minutes Using Gene Scissors
- Gut Microbiome Dysbiosis Linked to COVID-19
- Novel SARS CoV-2 Rapid Antigen Test Validated for Diagnostic Accuracy
- New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`
- AI Takes Guesswork Out Of Lateral Flow Testing
- Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting
- Rapid Antigen Tests Detect Omicron, Delta SARS-CoV-2 Variants
- Health Care Professionals Showed Increased Interest in POC Technologies During Pandemic, Finds Study
- Set Up Reserve Lab Capacity Now for Faster Response to Next Pandemic, Say Researchers
- Blood Test Performed During Initial Infection Predicts Long COVID Risk
- Low-Cost COVID-19 Testing Platform Combines Sensitivity of PCR and Speed of Antigen Tests
- Finger-Prick Blood Test Identifies Immunity to COVID-19
- Quick Test Kit Determines Immunity Against COVID-19 and Its Variants